mRNA Vaccines Market Report 2023-2033

mRNA Vaccines Market Report 2023-2033

The mRNA Vaccines Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Extensive research has been conducted on mRNA vaccines as potential cancer therapeutics for a period exceeding two decades, yielding limited success. In recent times, there has been a notable surge in research attention towards cancer vaccines. This surge has been prompted by the remarkable and enduring responses witnessed in certain malignancies through the use of immune checkpoint inhibitors, as well as advancements in technology. The initiation of a phase 3 clinical trial for the personalised vaccine mRNA-4157 (also referred to as V940) in conjunction with pembrolizumab (commonly known as Keytruda) was announced by Moderna and Merck on 26 July 2023. This trial aims to evaluate the efficacy of the combination therapy in high-risk patients who have previously undergone surgical intervention for melanoma. The objective of the trial is to recruit a total of 1,089 patients who are at stages IIb to IV. The primary endpoint of the trial is to assess the post-surgical recurrence-free survival of these patients. The conclusive outcomes are anticipated to be available by the year 2029.

What Questions Should You Ask before Buying a Market Research Report?

• How is the mRNA vaccines market evolving?
• What is driving and restraining the mRNA vaccines market?
• How will each mRNA vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each mRNA vaccines submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading mRNA vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the mRNA vaccines projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of

mRNA vaccines projects taking place now and over the next 10 years?

• Is there a greater need for product commercialisation to further scale the mRNA vaccines market?
• Where is the mRNA vaccines market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the mRNA vaccines market today, and over the next 10 years:

• Our 215-page report provides 93 tables and 130 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the mRNA vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Vaccine Type

• Self-amplifying mRNA-based Vaccines
• Conventional Non-amplifying mRNA-based Vaccines

Application

• Cancer
• Infectious Disease
• Autoimmune Diseases
• Others

End-users

• Hospitals and Clinics
• Research Organisations
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the mRNA Vaccines Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

• Pfizer Inc.
• Moderna, Inc.
• BioNTech SE
• AstraZeneca
• Sanofi
• GSK plc
• Daiichi Sankyo
• Ethris GmbH
• AIM Vaccine
• Arcturus Therapeutics Inc.
• CureVac
• Sino Biopharmaceutical Co., Ltd.

Overall world revenue for mRNA Vaccines Market, 2023 to 2033 in terms of value the market will surpass US$11,700.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the mRNA Vaccines Market, 2023 to 2033 report help you?

In summary, our 210+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for mRNA Vaccines Market 2023 to 2033, with forecasts for Vaccine type, application, and end-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 22 key national markets – See forecasts for the mRNA Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 12 of the major companies involved in the mRNA Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the mRNA Vaccines Market 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.